dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials
暂无分享,去创建一个
Moreno Ursino | Tim Friede | Nigel Stallard | A. Toumazi | Emmanuelle Comets | C. Alberti | F. Lentz | S. Zohar
[1] F Bretz,et al. Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies , 2005, Biometrics.
[2] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[3] J Whitehead,et al. A novel Bayesian decision procedure for early-phase dose-finding studies. , 1999, Journal of biopharmaceutical statistics.
[4] Sarah Zohar,et al. A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology , 2009, Clinical pharmacokinetics.
[5] Hartmut Derendorf,et al. Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development , 2000, Journal of clinical pharmacology.
[6] S. Piantadosi,et al. Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.
[7] France Mentré,et al. Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology , 2015, Pharmaceutical Research.
[8] Moreno Ursino,et al. Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations , 2017, Biometrical journal. Biometrische Zeitschrift.
[9] J Whitehead,et al. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. , 2001, Biostatistics.
[10] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[11] John Whitehead,et al. A Bayesian Approach for Dose-Escalation in a Phase I Clinical Trial Incorporating Pharmacodynamic Endpoints , 2007, Journal of biopharmaceutical statistics.